Your Notifications
All done, no notifications

What is Myelofibrosis?

Myelofibrosis is a chronic blood cancer and myeloproliferative neoplasm in which abnormal blood-forming cells and changes in the bone marrow environment cause progressive bone marrow fibrosis. As normal blood-cell production becomes impaired, patients may develop anemia, low platelet counts or abnormal white blood-cell counts. The spleen and liver may begin producing blood cells outside the bone marrow, which can enlarge these organs. Myelofibrosis may develop on its own as primary myelofibrosis or occur after another myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia.

What is the Importance of Timely Treatment?

Timely diagnosis and risk assessment are important because myelofibrosis can progress differently from one person to another. Some patients have stable disease and require regular monitoring, while others develop significant anemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms or progression to an advanced phase of disease. Early specialist assessment helps determine disease risk, monitor blood counts and symptoms, manage complications and identify patients who may be candidates for potentially disease-modifying treatment such as allogeneic stem-cell transplantation.

What are the Common Symptoms of Myelofibrosis?

  • Persistent fatigue and weakness
  • Shortness of breath, particularly with activity
  • Pale skin due to anemia
  • Unexplained weight loss
  • Fever or night sweats
  • Loss of appetite
  • Bone or muscle pain
  • Abdominal fullness or discomfort due to an enlarged spleen
  • Feeling full after eating a small amount
  • Easy bruising or bleeding
  • Frequent infections in some patients
  • Itching
  • Reduced exercise tolerance

Causes and Risk Factors of Myelofibrosis

Causes

  • Myelofibrosis develops when abnormal blood-forming stem or progenitor cells acquire genetic changes that promote uncontrolled or abnormal blood-cell production and release inflammatory signals that alter the bone marrow environment.
  • Mutations involving genes such as JAK2, CALR and MPL are commonly associated with myelofibrosis, although some patients do not have any of these driver mutations.
  • Primary myelofibrosis develops independently, while secondary myelofibrosis can develop after polycythemia vera or essential thrombocythemia.

Risk Factors

  • Increasing age
  • Presence of an underlying myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia
  • Certain acquired genetic mutations
  • Previous treatment or disease-related factors associated with secondary myelofibrosis
  • Certain adverse molecular or cytogenetic features associated with higher-risk disease

Latest Research and Technologies in the Treatment of Myelofibrosis in Singapore

  • Current myelofibrosis research is focused on improving symptom and spleen control, treating anemia and developing therapies that may alter disease progression. JAK inhibitors remain an important targeted treatment approach, while newer and investigational therapies are being studied for patients with anemia, thrombocytopenia, inadequate response or intolerance to existing treatments. Clinical research is also evaluating combinations of targeted therapies and approaches involving JAK inhibitors around allogeneic hematopoietic stem-cell transplantation.

Treatment options for Myelofibrosis

Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation is a potentially disease-modifying treatment and may be considered for selected patients with higher-risk disease who are medically suitable for transplantation. Pre-transplant disease control and donor selection are important parts of treatment planning.

Cost Start From 39000Explore Options

  • Clinical assessment:
    • Medical and Hematological Evaluation: A detailed history is taken to assess fatigue, weight loss, fever, night sweats, abdominal discomfort, bleeding, infections, bone pain and other constitutional symptoms.
    • Complete Blood Count and Peripheral Blood Assessment: A peripheral blood smear may show characteristic abnormalities, such as immature blood cells or teardrop-shaped red blood cells, and can provide additional information about abnormal blood-cell production.
    • Bone Marrow Evaluation: Bone marrow aspiration and biopsy are central to diagnosing myelofibrosis. The biopsy evaluates the degree and pattern of bone marrow fibrosis, abnormal megakaryocytes and other marrow changes.
    • Molecular and Cytogenetic Assessment: Cytogenetic testing can identify chromosomal abnormalities and may help assess risk.
    • Risk and Prognostic Assessment: Doctors assess clinical, laboratory, cytogenetic and molecular features to estimate disease risk and guide treatment decisions.
  • Imaging Tests:
    • Abdominal Ultrasound: Helps assess spleen and liver size and can monitor splenomegaly.
    • CT Scan: Provides a more detailed assessment of the spleen, liver, lymph nodes, and abdominal structures when needed.
    • MRI: May be used selectively to evaluate bone marrow or other areas when additional structural information is needed.
    • PET/CT: May be considered in selected situations when extramedullary disease or another complication requires further evaluation.
    • Imaging for Treatment Monitoring: Ultrasound or CT may monitor changes in spleen size during treatment.

MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive tele- rehabilitation services designed to support Myelofibrosis patients in Singapore. These services include:

  • Physical Activity and Exercise: Individually tailored physical activity can help maintain muscle strength, endurance and mobility, with intensity adjusted according to anemia, platelet levels, fatigue and overall health.
  • Nutritional Support: Dietitians can provide personalised nutrition guidance to support adequate calorie and protein intake, manage appetite loss and address nutritional deficiencies or treatment-related needs.
  • Fatigue Management: Structured activity planning, adequate rest, energy-conservation techniques and treatment of underlying anemia can help patients manage persistent fatigue.
  • Functional Rehabilitation: Patients with weakness, reduced exercise tolerance, pain or prolonged hospitalisation may benefit from physiotherapy and occupational therapy to maintain independence.
  • Psychological and Long-Term Support: Counselling, patient education and support programmes can help patients cope with a chronic blood cancer, treatment-related stress and the need for long-term monitoring or transplantation.
  • Medicines for myelofibrosis are selected according to symptoms, spleen enlargement, anemia, platelet counts, disease risk and previous treatment. JAK inhibitors may be used to reduce disease-related symptoms and splenomegaly in appropriate patients. Treatment of anemia may include red-blood-cell transfusions, erythropoiesis-supporting medicines or other selected therapies depending on the underlying cause and clinical circumstances. Additional medicines may be used to manage infections, bleeding, pain, constitutional symptoms or other complications.

Instantly Connect with our Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8

Hospitals for Myelofibrosis in Singapore

Farrer Park Hospital: Top Doctors, and Reviews
Farrer Park Hospital

Singapore, Singapore

Apart from in-detail treatment procedures available, Farrer Park Hospital located in Connexion, Singapore has a wide variety of facilities available for International Patients. Some of the facilities which are provided by them are Accommodation, Airport Transfer, Choice of Meals, Interpreter, SIM, TV inside room. Also listed below are some of the most prominent infrastructural details:

  • A medical centre is linked to the Farrer Park Hospital Complex, Connexion, Singapore
  • The focus of the hospital is to bring together two essential elements: those of healthcare combined with hospitality.
  • There is a building with 20 different stories which comprises Owen Link, hotel and spa.
  • Personal attention and patient care focus is maintained with a system in place of listening, analysing, evaluating and then implementing a treatment plan.
  • 121 bed capacity
  • Technology and innovations help provide the best of medical and surgical treatment options.
  • Professionally implemented international patient care systems
  • Suites: Cardiovascular, day surgery, endoscopy, major surgery, nuclear medicine, radiation oncology, and inpatient suite
  • Diagnostic imaging and intensive care unit
  • 24 hour emergency clinic and pharmacy
  • Facilities such as dialysis, nutrition services, rehab centre, and teaching clinic
Message Us

279

PROCEDURE

14

SPECIALITIES

7+

FACILITIES & AMENITIES

Our Services to better your experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Why Choose Singapore for Myelofibrosis Treatment?

  • Multidisciplinary Hematology Care: Patients can access hematologists, hemato-oncologists, transfusion specialists, transplant physicians and supportive-care teams according to their clinical needs.
  • Advanced Diagnostic Facilities: Specialised centres may provide bone marrow biopsy, molecular testing for myelofibrosis-associated mutations, cytogenetic analysis and advanced imaging.
  • Targeted Treatment Options: Eligible patients may receive modern JAK-inhibitor therapy and supportive treatments based on disease characteristics and blood counts.
  • Stem-Cell Transplantation: Major transplant centres can evaluate suitable patients for allogeneic hematopoietic stem-cell transplantation, including donor assessment and post-transplant monitoring.
  • Comprehensive Support and International Patient Services: Blood transfusion support, nutritional counselling, rehabilitation, follow-up care and international-patient coordination can be incorporated into the treatment pathway.

Frequently Asked Questions

Myelofibrosis is generally a chronic blood cancer rather than a condition with a fixed recovery period. Treatment may control symptoms and complications for extended periods, while selected patients undergoing allogeneic stem-cell transplantation require a prolonged recovery and long-term follow-up. Recovery varies by disease risk, treatment type, age, and overall health.

Yes. Many people with myelofibrosis can walk and remain physically active. However, severe anemia, fatigue, enlarged spleen, bone pain or low platelet counts may limit physical activity. Adjust exercise based on blood counts, symptoms, and advice from the treating healthcare team.

Major Singapore hematology and oncology centres may provide bone marrow biopsy, molecular and cytogenetic testing, advanced imaging, transfusion support, targeted medicines and allogeneic stem-cell transplantation for appropriately selected patients.

Many major Singapore hospitals have international-patient departments that can assist with medical records, specialist consultations, treatment coordination, travel arrangements, accommodation and follow-up care.

Consider a centre with experienced hematologists and hemato-oncologists, access to molecular and cytogenetic testing, transfusion support and modern myelofibrosis treatments. If transplantation may be appropriate, consider a centre with an established allogeneic stem-cell transplant programme and appropriate supportive-care facilities.

There is no single success rate for myelofibrosis treatment. Outcomes depend on disease risk, age, blood counts, molecular and cytogenetic characteristics, symptoms, treatment response and overall health. JAK inhibitor treatment can control symptoms and spleen size, while allogeneic stem-cell transplantation can provide long-term disease control in selected patients.

Hematologists and hemato-oncologists at specialised Singapore centres manage myelofibrosis, including symptomatic disease, anemia, splenomegaly, treatment complications and advanced disease. Patients who may require transplantation should consider centres with experience in allogeneic hematopoietic stem-cell transplantation.

Risks depend on the treatment used and the patient's blood counts and overall health. JAK inhibitors can cause treatment-related blood-count abnormalities and other adverse effects. Transfusions and other supportive treatments also have potential complications, while allogeneic stem-cell transplantation carries significant risks including infections, graft-versus-host disease, organ complications and treatment-related mortality. Treatment risks should be discussed individually with the treating hematologist.

Myelofibrosis does not typically cause structural physical deformities. However, chronic anemia, bone pain, muscle weakness, enlarged organs and complications of advanced disease can result in long-term functional limitations in some patients.

Yes. Myelofibrosis can progress and may lead to worsening anemia, thrombocytopenia, symptomatic splenomegaly, infections, bleeding and other complications. In some patients, the disease can progress to an accelerated or blast phase and may transform into acute myeloid leukemia.

There is no established way to prevent primary myelofibrosis because it is associated with acquired genetic changes that generally cannot be predicted or prevented. For people with polycythemia vera or essential thrombocythemia, regular hematology follow-up and appropriate management can help monitor for disease progression and complications.

Myelofibrosis is more frequently diagnosed in older adults and is uncommon in younger people. Risk is also relevant in people who already have myeloproliferative neoplasms such as polycythemia vera or essential thrombocythemia, which can develop into secondary myelofibrosis.

Author

Pragun Gupta
Pragun Gupta

Doctor of Pharmacy

1 Year of Experience

Pragun Gupta is a Doctor of Pharmacy (Pharm. D.) professional from Teerthanker Mahaveer University with hands-on experience in clinical pharmacology, clinical research, and evidence-based medical writing. Through her clinical and research exposure, she has developed a strong interest in pharmacoeconomics, pharmacology, therapeutics, and pharmacovigilance.

As a medical writer, she works on medical and scientific research articles, patient education materials, and healthcare-focused content. Her clinical research and evidence-based writing experience enables her to translate complex medical information into clear, accurate, patient-friendly content while maintaining scientific credibility and medical accuracy. Her primary aim is to make healthcare information accessible and easy for patients and general readers to understand.

View More

Reviewer

Dr. Akash Khandelwal
Dr. Akash Khandelwal

Hematologist

9 Years of Experience

Dr. Akash Khandelwal is a distinguished Hematologist, Hemato-oncologist, and Bone Marrow Transplant (BMT) Physician with extensive training from the prestigious AIIMS New Delhi. His expertise encompasses a wide range of specialized techniques in bone marrow transplantation, including autologous and allogeneic transplants such as matched sibling donors, matched unrelated donors (MUD), and haploidentical donor transplants. Dr. Khandelwal has personally supervised and conducted over 100 bone marrow transplants. View More

Last Reviewed - January 2026